* Iveric Bio Inc ISEE.OQ ISEE.O is expected to show no
change
in quarterly revenue when it reports results on May 4.
* Refinitiv's mean analyst estimate for Iveric Bio Inc is
for a
loss of 29 cents per share. For the same quarter last year, the
company reported a loss of 29 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.
* Wall Street's median 12-month price target for Iveric Bio
Inc is
$25, above its last closing price of $13.85.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2021 -0.24 -0.25 -0.29 Missed -18.2
Sep. 30 2021 -0.29 -0.29 -0.23 Beat 20.1
Jun. 30 2021 -0.26 -0.26 -0.32 Missed -22.8
Mar. 31 2021 -0.25 -0.25 -0.29 Missed -16.5
Dec. -0.26 -0.27 Missed -5.5
31 2020
Sep. 30 2020 -0.22 -0.22 -0.27 Missed -23.6
Jun. 30 2020 -0.31 -0.31 -0.32 Missed -3.2
Mar. 31 2020 -0.39 -0.39 -0.28 Beat 28.2
This summary was machine generated May 2 at 18:31 GMT. All
figures in US dollars unless otherwise stated